Biochem/physiol Actions
Primary TargetNMDA receptors
Target IC50: 0.015 and 0.078 µM for NR2A and NR2B, respectively.
General description
A potent antagonist for NMDA receptors. Modestly higher selectivity for the NR2A than for the NR2B containing NMDA receptors (IC50 = 0.015 and 0.078 µM) but insufficient to discriminate between NR2A and NR2B-containing NMDA receptors. Widely used for researches in synaptic plastic, learning and memory, and epilepsy.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Other Notes
Frizelle. P., et al. 2006. Mol. Pharmacol.70, 1022.Milton, A., et al. 2013. J. Neurosci.33, 1109.Kochlamazashvili, G., et al. 2012. J. Neurosci.32, 2263.Kocsis, B., et al. 2012. Sleep.35, 1011.
Reconstitution
Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
Warning
Toxicity: Standard Handling (A)
This product has met the following criteria to qualify for the following awards: